Oculus Innovative Services Leaps on FDA Approval for New Applications of Microcyn (OCLS)
Wednesday, March 10, 2010 - 12:18
Written on Wed, 03/10/2010 - 12:18pm
By Chip Brian

3/10/2010-Shares of Oculus Innovative Services (NASDAQ:OCLS) are trading 34.8% higher to $2.44 Wednesday after the company announced that it has received new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for new dermatology indications for Microcyn(R) Skin and Wound HydroGel.
Microcyn Skin and Wound HydroGel is a prescription product is intended for use under the supervision of a healthcare professional for management of wounds including itch and pain relief associated with dermal irritation, sores, injuries and ulcers of dermal tissue.
Hoji Alimi, founder and CEO of Oculus, commented, "We are especially excited to receive our first FDA clearance for the Microcyn HydroGel for dermatology indications including the reduction of itch and pain relief for troublesome skin afflictions."
SmarTrend is bullish on shares of OCLS and our subscribers were alerted to Buy on December 04, 2009 at $2.04. The stock has risen 20.6% since the alert was issued.

Keywords: oculus microcyn Stock fda approval smartrend

Ticker(s): OCLS

Contact Chip Brian



Smartrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.mysmartrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at http://www.mysmartrend.com/morning-call-newsletter-signup.